New Pig Model May Better Capture ALS at Its Earliest Stages
A new pig model of amyotrophic lateral sclerosis (ALS) more accurately reflects the gradual motor neuron loss and disease…
Articles by Steve Bryson, PhD
Phase 1 Safety Study Clears Path to Test Utreloxastat in ALS Patients
Utreloxastat (PTC857), an investigational therapy for people with amyotrophic lateral sclerosis (ALS), was safe, well tolerated, and displayed promising…
FDA Seeks Input on Tofersen’s Approval for ALS
The U.S. Food and Drug Administration (FDA) has announced an advisory committee meeting seeking advice on whether to approve…
EpiSwitch Test May Help Classify ALS Patients: New Trial Data
EpiSwitch, a non-invasive, blood-based test developed by Oxford BioDynamics, successfully stratified patients with amyotrophic lateral sclerosis (ALS) as…
Antisense Therapy Safely Dampens Mutant C9orf72 in ALS Patient
An experimental antisense oligonucleotide that works to suppress the mutant C9orf72 gene — a cause of amyotrophic lateral sclerosis (ALS) —…
Measuring Electrical Brain Activity Helps Identify 4 ALS Subtypes
Amyotrophic lateral sclerosis (ALS) can be grouped into four disease subtypes based on patterns of changes in electrical signals…
FDA Grants Priority Review to ALS Therapy AMX0035
The U.S. Food and Drug Administration (FDA) has accepted for review Amylyx Pharmaceuticals‘ application seeking approval of AMX0035…
Combined Gene Therapy Shows Promise, but Not Synergy, in Mice
A combined gene therapy that delivered two nerve growth factors — NRG1-I and NRG1-III — to muscle and nerve cells…
Age-related Loss in Cell’s Control Over Protein Levels Tied to Clumping
The loss of chemical modifications in the regulatory sequence of the TARDBP gene, called DNA methylation, seems to contribute to…
Study of Perampanel for ALS Stopped Due to Adverse Events
A small open-label study evaluating the epilepsy medication perampanel in adults with amyotrophic lateral sclerosis (ALS) was halted due…